Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:31:17.285Z.
Calculation as of: 2026-10-06T18:31:17.285Z.
Quote observation: 2026-10-06T18:29:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
enGene Holdings Inc.
Market Cap
$120.92M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| enGene Holdings Inc. (ENGN) | $120.92M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.50M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.23M | N/A |
| BGM Group Ltd. (BGM)vs › | $122.81M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.68M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.98M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.45M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.65M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
